View in EDS HTML Full Text PDF Full Text

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.

Saved in:
Bibliographic Details
Title: Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Authors: Vissers MFJM; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Heuberger JAAC; Centre for Human Drug Research, Leiden, The Netherlands., Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands., Oude Nijhuis J; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., De Deyn PP; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Hadi S; PRA Health Sciences, Groningen, The Netherlands., Harris J; Denali Therapeutics Inc., South San Francisco, California, USA., Tsai RM; Denali Therapeutics Inc., South San Francisco, California, USA., Cruz-Herranz A; Denali Therapeutics Inc., South San Francisco, California, USA., Huang F; Denali Therapeutics Inc., South San Francisco, California, USA., Tong V; Denali Therapeutics Inc., South San Francisco, California, USA., Erickson R; Denali Therapeutics Inc., South San Francisco, California, USA., Zhu Y; Denali Therapeutics Inc., South San Francisco, California, USA., Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, California, USA., Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, California, USA., Tang X; Denali Therapeutics Inc., South San Francisco, California, USA., Chang M; Denali Therapeutics Inc., South San Francisco, California, USA., Fox BM; Denali Therapeutics Inc., South San Francisco, California, USA., Estrada AA; Denali Therapeutics Inc., South San Francisco, California, USA., Pomponio RJ; Sanofi Genzyme, Cambridge, Massachusetts, USA., Alonso-Alonso M; Sanofi Genzyme, Cambridge, Massachusetts, USA., Zilberstein M; Sanofi Genzyme, Cambridge, Massachusetts, USA., Atassi N; Sanofi Genzyme, Cambridge, Massachusetts, USA., Troyer MD; Denali Therapeutics Inc., South San Francisco, California, USA., Ho C; Denali Therapeutics Inc., South San Francisco, California, USA.
Source: Clinical and translational science [Clin Transl Sci] 2022 Aug; Vol. 15 (8), pp. 2010-2023. Date of Electronic Publication: 2022 Jun 01.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35649245
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Vissers+MFJM%22">Vissers MFJM</searchLink>; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Heuberger+JAAC%22">Heuberger JAAC</searchLink>; Centre for Human Drug Research, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Groeneveld+GJ%22">Groeneveld GJ</searchLink>; Centre for Human Drug Research, Leiden, The Netherlands.; Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Oude+Nijhuis+J%22">Oude Nijhuis J</searchLink>; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22De+Deyn+PP%22">De Deyn PP</searchLink>; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Hadi+S%22">Hadi S</searchLink>; PRA Health Sciences, Groningen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Harris+J%22">Harris J</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+RM%22">Tsai RM</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Cruz-Herranz+A%22">Cruz-Herranz A</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Huang+F%22">Huang F</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Tong+V%22">Tong V</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Erickson+R%22">Erickson R</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Zhu+Y%22">Zhu Y</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Scearce-Levie+K%22">Scearce-Levie K</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Hsiao-Nakamoto+J%22">Hsiao-Nakamoto J</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Tang+X%22">Tang X</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chang+M%22">Chang M</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Fox+BM%22">Fox BM</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Estrada+AA%22">Estrada AA</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Pomponio+RJ%22">Pomponio RJ</searchLink>; Sanofi Genzyme, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Alonso-Alonso+M%22">Alonso-Alonso M</searchLink>; Sanofi Genzyme, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Zilberstein+M%22">Zilberstein M</searchLink>; Sanofi Genzyme, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Atassi+N%22">Atassi N</searchLink>; Sanofi Genzyme, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Troyer+MD%22">Troyer MD</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ho+C%22">Ho C</searchLink>; Denali Therapeutics Inc., South San Francisco, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2022 Aug; Vol. 15 (8), pp. 2010-2023. <i>Date of Electronic Publication: </i>2022 Jun 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35649245
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cts.13317
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2010
    Titles:
      – TitleFull: Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vissers MFJM
      – PersonEntity:
          Name:
            NameFull: Heuberger JAAC
      – PersonEntity:
          Name:
            NameFull: Groeneveld GJ
      – PersonEntity:
          Name:
            NameFull: Oude Nijhuis J
      – PersonEntity:
          Name:
            NameFull: De Deyn PP
      – PersonEntity:
          Name:
            NameFull: Hadi S
      – PersonEntity:
          Name:
            NameFull: Harris J
      – PersonEntity:
          Name:
            NameFull: Tsai RM
      – PersonEntity:
          Name:
            NameFull: Cruz-Herranz A
      – PersonEntity:
          Name:
            NameFull: Huang F
      – PersonEntity:
          Name:
            NameFull: Tong V
      – PersonEntity:
          Name:
            NameFull: Erickson R
      – PersonEntity:
          Name:
            NameFull: Zhu Y
      – PersonEntity:
          Name:
            NameFull: Scearce-Levie K
      – PersonEntity:
          Name:
            NameFull: Hsiao-Nakamoto J
      – PersonEntity:
          Name:
            NameFull: Tang X
      – PersonEntity:
          Name:
            NameFull: Chang M
      – PersonEntity:
          Name:
            NameFull: Fox BM
      – PersonEntity:
          Name:
            NameFull: Estrada AA
      – PersonEntity:
          Name:
            NameFull: Pomponio RJ
      – PersonEntity:
          Name:
            NameFull: Alonso-Alonso M
      – PersonEntity:
          Name:
            NameFull: Zilberstein M
      – PersonEntity:
          Name:
            NameFull: Atassi N
      – PersonEntity:
          Name:
            NameFull: Troyer MD
      – PersonEntity:
          Name:
            NameFull: Ho C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2022 Aug
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1752-8062
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Clinical and translational science
              Type: main
ResultId 1